Search
Rilonacept
go.drugbank.com/drugs/DB06372ApprovedInvestigationalRilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. … Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome (FCAS)
Categories: Interleukin-1 Receptor Accessory ProteinAlmonertinib
go.drugbank.com/drugs/DB16640ApprovedInvestigational[A231859, A231864, A231869] Unlike other third-generation EGFR TKIs, almonertinib is a pyrimidine-based drug that forms a covalent bond to the binding site of the EGFR tyrosine kinase domain. … [A231859] On March 19, 2020, almonertinib was approved in China for the treatment of EGFR T790M+ non-small cell lung cancer.[A231864] Almonertinib was also approved by the EMA on February 20, 2026.
Categories: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitorsP2 Purinoceptors
go.drugbank.com/bio_entities/BE0009827TargetPutative receptor for purines coupled to G proteins … Receptor for ADP. Coupled to G(i)-proteins. May play a role in hematopoiesis and the immune system
Polypeptides: Lysophosphatidic acid receptor 4, Lysophosphatidic acid receptor 6Synonyms: LPA receptor 4, LPA receptor 6Drometrizole trisiloxane
go.drugbank.com/drugs/DB11585ApprovedDespite being used elsewhere in the world with relatively few reports of adverse reactions, the FDA continues to cite that the existing scientific record is not sufficient to establish the compound as … The compound is a lipophilic benzotriazole derivative marketed as Meroxyl XL by L'Oreal, although sunscreens with drometrizole trisiloxane are currently only approved for use in the EU, Canada, Australia
Interferon alfacon-1
go.drugbank.com/drugs/DB00069ApprovedWithdrawnThe 166-amino acid sequence of Interferon alfacon-1 was derived by scanning the sequences of several natural interferon alpha subtypes and assigning the most frequently observed amino acid in each corresponding … Prior to final purification, Interferon alfacon-1 is allowed to oxidize to its native state, and its final purity is achieved by sequential passage over a series of chromatography columns.
Rurioctocog alfa pegol
go.drugbank.com/drugs/DB16007ApprovedInvestigationalThe presence of the polyethylene glycol (PEG) moiety increases the plasma half-life of the drug, thereby increasing the drug's duration of action.[L40099] … [A245149] Hemophilia A is the most common inherited bleeding disorder leading to deficiency of factor VIII, which is caused by defects in the F8C gene that encodes coagulation factor VIII.
P2X purinoceptor 4
go.drugbank.com/bio_entities/BE0005793TargetHumansPromotes the differentiation and activation of Th17 cells via expression of retinoic acid-related orphan receptor C/RORC (PubMed:35165166).
Synonyms: ATP receptor, Purinergic receptorP2Y purinoceptor 1
go.drugbank.com/bio_entities/BE0009816TargetHumansReceptor for extracellular adenine nucleotides such as ADP (PubMed:25822790, PubMed:9038354, PubMed:9442040).
Synonyms: ADP receptor, Purinergic receptorFunction: A1 adenosine receptor bindingSuzetrigine
go.drugbank.com/drugs/DB18927ApprovedInvestigational[A264953] On January 30, 2025, suzetrigine was approved by the FDA as a first-in-class non-opioid analgesic.[L52098] … Suzetrigine is a Na<sub>V</sub>1.8 voltage-gated sodium channel blocker with analgesic properties[A264948] Na<sub>V</sub>1.8 is abundantly expressed in peripheral sensory nerves to play a role in pain
Anthrax immune globulin human
go.drugbank.com/drugs/DB09057ApprovedInvestigationalto grow and produce anthrax toxins. … Available as the product Anthrasil (FDA), the result is a solution for slow IV infusion containing polyclonal antibodies that bind the protective antigen (PA) component of Bacillus anthracis lethal and